Survival protein anoctamin-6 controls multiple platelet responses including phospholipid scrambling, swelling, and protein cleavage

Citation for published version (APA):

Mattheij, N. J. A., Braun, A., van Kruchten, R., Castoldi, E., Pircher, J., Baaten, C. C. F. M. J., Wuelling, M., Kuijpers, M. J. E., Koehler, R., Poole, A. W., Schreiber, R., Vortkamp, A., Collins, P. W., Nieswandt, B., Kunzelmann, K., Cosemans, J. M. E. M., & Heemskerk, J. W. M. (2016). Survival protein anoctamin-6 controls multiple platelet responses including phospholipid scrambling, swelling, and protein cleavage. *Faseb Journal*, 30(2), 727-737. <https://doi.org/10.1096/fj.15-280446>

Document status and date:

Published: 01/02/2016

DOI:

[10.1096/fj.15-280446](https://doi.org/10.1096/fj.15-280446)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Vaccine Discovery and Development: Lessons from COVID-19

Free eBook

Emerging infectious diseases (EIDs) can evolve into a global healthcare crisis or pandemic. Scientists have previously required years to develop vaccines or therapeutics. The use of high throughput technology can greatly broaden the insights collected during discovery, augment efficiency and safety of handling EIDs, and shorten timelines.

Download this publication for an overview of many lessons learned in virology, immunology, and vaccine research during COVID-19 vaccine development.

[Download here](#)

Survival protein anoctamin-6 controls multiple platelet responses including phospholipid scrambling, swelling, and protein cleavage

Nadine J. A. Mattheij,* Attila Braun,[†] Roger van Kruchten,* Elisabetta Castoldi,* Joachim Pircher,[‡] Constance C. F. M. J. Baaten,* Manuela Wüiling,[§] Marijke J. E. Kuijpers,* Ralf Köhler,[¶] Alastair W. Poole,^{||} Rainer Schreiber,[#] Andrea Vortkamp,[§] Peter W. Collins,** Bernhard Nieswandt,[†] Karl Kunzelmann,[#] Judith M. E. M. Cosemans,* and Johan W. M. Heemskerk^{*1}

*Department of Cell Biochemistry of Thrombosis and Haemostasis Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, Maastricht, The Netherlands;

[†]Department of Experimental Biomedicine, University Hospital and Rudolf Virchow Center, University of Würzburg, Würzburg, Germany; [‡]Walter Brendel Centre of Experimental Medicine and German Centre of Cardiovascular Research, Munich Heart Alliance, Ludwig-Maximilians-Universität München, München, Germany; [¶]Department of Developmental Biology, Centre for Medical Biotechnology, University of Duisburg-Essen, Duisburg-Essen, Germany; [§]Aragon Institute of Health Sciences I+CS/IIS and ARAID, Zaragoza, Spain; ^{||}School of Physiology and Pharmacology, University of Bristol, Bristol, United Kingdom; [#]Institute of Physiology, University of Regensburg, Regensburg, Germany; **Arthur Bloom Haemophilia Centre, School of Medicine, Cardiff University, Cardiff, United Kingdom

ABSTRACT Scott syndrome is a rare bleeding disorder, characterized by altered Ca^{2+} -dependent platelet signaling with defective phosphatidylserine (PS) exposure and microparticle formation, and is linked to mutations in the *ANO6* gene, encoding anoctamin (Ano)6. We investigated how the complex platelet phenotype of this syndrome is linked to defective expression of Anos or other ion channels. Mice were generated with heterozygous or homozygous deficiency in *Ano6*, *Ano1*, or Ca^{2+} -dependent $\text{K}_{\text{Ca}3.1}$ Gardos channel. Platelets from these mice were extensively analyzed on molecular functions and compared with platelets from a patient with Scott syndrome. Deficiency in *Ano1* or Gardos channel did not reduce platelet responses compared with control mice ($P > 0.1$). In 2 mouse strains, deficiency in *Ano6* resulted in reduced viability with increased bleeding time to 28.6 min (control 6.4 min, $P < 0.05$). Platelets from the surviving *Ano6*-deficient mice resembled platelets from patients with Scott syndrome in: 1) normal collagen-induced aggregate formation ($P > 0.05$) with reduced PS exposure (–65 to 90%); 2) lowered Ca^{2+} -dependent swelling (–80%) and membrane blebbing (–90%); 3) reduced calpain-dependent protein cleavage (–60%); and 4) moderately affected apoptosis-dependent PS exposure. In conclusion, mouse deficiency of *Ano6* but not of other channels affects viability and phenocopies the complex changes in platelets from hemostatically impaired patients with Scott syndrome.—Mattheij, N. J. A., Braun, A., van Kruchten, R., Castoldi, E., Pircher, J., Baaten, C. C. F. M. J., Wüiling, M.,

Kuijpers, M. J. E., Köhler, R., Poole, A. W., Schreiber, R., Vortkamp, A., Collins, P. W., Nieswandt, B., Kunzelmann, K., Cosemans, J. M. E. M., Heemskerk, J. W. M. Survival protein anoctamin-6 controls multiple platelet responses including phospholipid scrambling, swelling, and protein cleavage. *FASEB J.* 30, 727–737 (2016). www.fasebj.org

Key Words: bleeding • embryonic lethality • phosphatidylserine • Scott syndrome • TMEM16F

The uncommon Scott syndrome is characterized as a mild bleeding disorder associated with low prothrombin consumption in blood serum. Platelets from patients with Scott syndrome show a defect in Ca^{2+} -induced phosphatidylserine (PS) exposure and microparticle formation, but unchanged Ca^{2+} signaling and aggregation (1–4). It has long been recognized that the defective PS exposure in blood cells from patients with Scott syndrome results from impaired phospholipid scrambling, a process that normally abolishes the asymmetric distribution of PS and phosphatidylethanolamine over the plasma membrane upon persistent elevation of cytosolic Ca^{2+} (5–7). A consequence of the defective PS exposure is a markedly impaired procoagulant activity of platelets, which agrees with the bleeding phenotype (8). On the other hand, PS exposure induced

¹ Correspondence: Chair of Cell Biochemistry of Thrombosis and Haemostasis Biochemistry, CARIM, Maastricht University PO Box 616, 6200 MD, Maastricht, The Netherlands. E-mail: jwm.heemskerk@maastrichtuniversity.nl
doi: 10.1096/fj.15-280446

This article includes supplemental data. Please visit <http://www.fasebj.org> to obtain this information.

Abbreviations: AF647, Alexa Fluor 647; Ano, anoctamin; GPVI, glycoprotein VI; PE, phycoerythrin; PRP, platelet-rich plasma; PS, phosphatidylserine

by apoptosis (9) is little affected in the blood cells from patients with Scott syndrome (10, 11).

Recently, in 2 unrelated patients with Scott syndrome, dysfunctional mutations have been identified in the *ANO6* gene (alternatively named *TMEM16F*), which codes for the integral membrane protein anoctamin (Ano)6 (12, 13). In a murine B-cell line model, the silencing of *Ano6* resulted in an impairment of Ca^{2+} -dependent PS exposure (12). A role of Anos as transporters for the negatively charged PS was also confirmed by structural analysis (14). In addition, there is substantial electrophysiological evidence that Ano6, like other members of the Ano family, can operate as a Ca^{2+} -induced ion channel that is permeable to chloride ions, monovalent cations, and calcium ions (10, 15–17). We and others have reported that in blood cells from patients with Scott syndrome (10) and Ano6-deficient mice (17), this ion conductance is markedly reduced. Hence, the question arises which other (patho)physiological relevant functions are regulated by Ano6 rather than only Ca^{2+} -dependent phospholipid scrambling. Several observations in the literature are compatible with a broader role of Ano6. For instance, platelets from patients with Scott syndrome show reduced Ca^{2+} -dependent microvesiculation (1, 3), impaired inactivation of the integrin $\alpha_{\text{IIb}}\beta_3$ (18), and defective aging-dependent PS exposure (19).

On the other hand, Scott platelets are not completely devoid of PS exposure and procoagulant activity, when stimulated with Ca^{2+} -mobilizing agonists such as thrombin plus collagen (6, 11). This suggests involvement of other proteins besides Ano6 in the regulation of Ca^{2+} -induced phospholipid scrambling. In platelets as well as erythrocytes, a role in PS exposure has been proposed for volume-sensitive Cl^- channels (20) and for intermediate conductance Ca^{2+} -activated K^+ channels, known as $\text{K}_{\text{Ca}3.1}$ or Gardos channels (21, 22). Furthermore, overexpression studies suggest that also other members of the Ano family can contribute to PS exposure (23). In particular, the isoform Ano1 is of interest, because in erythrocytes it regulates α -hemolysin-induced phospholipid scrambling (24). Hence, the question can be raised if a gene defect in *ANO6* alone is sufficient for the altered blood cell properties in the Scott syndrome.

In the present study, we used several molecular and functional approaches to unravel the apparently multiple and nonredundant functions of Ano6 in platelets and erythrocytes. We compared the alterations in platelet properties of a patient with Scott syndrome with platelets from healthy control subjects and furthermore compared the platelet properties of several new strains of Ano6-deficient mice, as well as from mice lacking Ano1 or Gardos channels. Our data point to a remarkable set of phenotypic changes linked to defective Ano6 expression in both humans and mice, including low residual Ca^{2+} -dependent PS exposure, absence of swelling morphologic changes, presence of alternative Ano6 splice variants, and a moderate bleeding tendency.

MATERIALS AND METHODS

Materials

ABT-737 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), annexin A5 labeled with FITC was from PharmaTarget (Maastricht, The Netherlands); Alexa Fluor 647

(AF647)-labeled annexin A5 and ionomycin were purchased from Invitrogen (Carlsbad, CA, USA). The glycoprotein VI (GPVI) agonist convulxin was purified, as described previously (25). FITC-labeled anti-mouse CD62P (P-selectin) mAb as well as phycoerythrin (PE)-conjugated JON/A mAb directed against the active conformation of mouse integrin $\alpha_{\text{IIb}}\beta_3$ were from Emfret Analytics (Würzburg, Germany). Human α -thrombin was from Sigma-Aldrich (St. Louis, MO, USA). Affinity-purified polyclonal rabbit antibodies directed against human and mouse Ano1 (DOG-1) and Ano6 (G-14 against extracellular domain) were from Santa Cruz, anti- α -tubulin mAb came from Abcam (Cambridge, MA, USA). Rabbit antibody directed against mouse $\text{K}_{\text{Ca}3.1}$ was obtained as described previously (26). Sources of other materials were as reported elsewhere (18).

Blood donors

Blood was obtained from healthy volunteers and an accessible patient with Scott syndrome, after full informed consent (Helsinki declaration), under protocols reviewed by the local ethics committees. The patients with Scott syndrome have been genotyped as compound heterozygous for 2 different mutations in the *ANO6* gene (alias *TMEM16F*), with 1 splicing mutation (IVS6 + 1G→A) causing exon 6 skipping, and another mutation in exon 11 (c.1219insT) leading to a premature stop of translation (13). An analysis of splice variants is described in the supplemental materials (Supplemental Fig. S1).

Animals

Mouse experiments were approved by the local animal care and use committees. Experiments were performed using genetically modified and corresponding wild-type animals from the same breeding, simultaneously at the same location. Mice with a homozygous deficiency of the Gardos channel $\text{K}_{\text{Ca}3.1}$ (*Kcnn4*^{−/−}) and wild-type littermates (*Kcnn4*^{+/+}) had a mixed 129Sv/C57BL/6 background and were generated and genotyped as described elsewhere (27). Homozygous *Kcnn4*^{−/−} mice suffer from hypertension, but survive normally (27, 28). Mice with megakaryocytes and platelets homozygously deficient in Ano1 (*Ano1* gene, alias *Tmem16a*) were generated by crossing *Ano1*^{fl/fl} mice with transgenic mice expressing a Cre-recombinase after the PF4 promoter (C57BL/6 background). The mice were genotyped using the following nucleotide primers: wild-type *Ano1*^{+/+} (229 bp, 2165 bp in flox) GCAGAAAAGT GCCAGAGACC (forward), TTTCCAATGG CCTAGACCTG (reverse); for *Ano1*^{−/−} (462 bp in flox) ATAGCAGCTT TGCTCCTTCG (forward), CTCGTCCTGC AGTTCATTCA (reverse).

In 2 laboratories (Würzburg, Regensburg), the AW-382 embryonic stem cell clone *Ano6*^{gt(AW0382)} (*Ano6*^{AW}; Wellcome Trust Sanger Institute; Mouse Genome Informatics: 3857206, stock number 020701-UCD) was used to generate mice with genetic deficiency of *Ano6* (alias *Tmem16f*). The embryonic stem cell clone contains a β -geo reporter gene trap in intron 3 of *Ano6*, which disturbs mRNA transcription and synthesis of the protein. Male chimeras derived from the embryonic stem cell line were bred with C57BL/6 females to generate heterozygous *Ano6*^{AW/+} mice. The latter were cross-bred at C57BL/6 background to obtain homozygous deficient mice. Presence of the gene trap cassette was detected by PCR using the following primers: TTATCGATGA GCGTGGTGGT TATGC (forward); GCGCGTACAT CGGGCAAATA ATATC (reverse).

In addition, mice from the *Ano6*^{tm1A^{vor}} (*Ano6*^{A^{vor}}) strain were used, generated as described elsewhere (29). To reduce postnatal lethality of homozygous mutants, *Ano6*^{A^{vor}+/−} mice were crossed on a C57BL6L background to obtain *Ano6*^{A^{vor}−/−} animals. Mice were genotyped for heterozygous or homozygous deficiency in

Ano6 expression by PCR (29). Per strain, wild-types were used from the same breeding. Analysis of murine *Ano6* splice variants is described in (Supplemental Fig. S4).

Embryonic development

Inbred, pregnant female *Ano6*^{+/-} mice were killed at gestational d 10.5, 12.5, or 16.5. Viable embryos and death bodies were counted, and embryos were checked for macroscopic abnormalities.

Blood collection and isolation of platelets and erythrocytes

Human blood was collected into PPACK/fragmin for flow perfusion studies, as described previously (30). Other samples were collected into trisodium citrate for preparation of platelet-rich plasma (PRP) (31) or into acid-citrate-dextrose anticoagulant for preparation of isolated platelets (18). Washed cells were suspended into HEPES buffer pH 7.45 (10 mM HEPES, 136 mM NaCl, 2.7 mM KCl, 2 mM MgCl₂, 5 mM glucose, and 0.1% bovine serum albumin); 2 mM CaCl₂ was added directly before the experiments. Cell concentrations were determined with a Beckman Coulter (Brea, CA, USA) counter.

Blood was obtained from adult mice *via* orbital puncture under anesthesia, according to the local ethical permissions. Mouse blood was collected into PPACK/heparin/fragmin for flow perfusion studies, as described elsewhere (32). Blood was also collected into trisodium citrate for preparation of PRP (18). For platelet isolation, mouse blood was taken into 1/6 volume of acid-citrate-dextrose anticoagulant (85 mM sodium citrate, 78 mM citric acid, and 11 mM D-glucose). Platelets (18) and erythrocytes (22) were separated by centrifugation, washed, and suspended in modified HEPES buffer pH 7.45 (5 mM HEPES, 136 mM NaCl, 2.7 mM KCl, 2 mM MgCl₂, 0.42 mM Na₂HPO₄, 5 mM glucose, and 0.1% bovine serum albumin); 2 mM CaCl₂ was added directly before the experiments. Cell concentrations were determined with a Coulter counter.

Flow cytometric analyses

Suspensions of washed human platelets were activated, as described elsewhere (11). Washed mouse platelets in suspension (1×10^{11} /L) were stimulated in the presence of 2 mM CaCl₂ with indicated agonists or vehicle at room temperature. Platelet samples were analyzed for PS after 30 min of activation and labeling with AF647-annexin A5 (1:200) (18). Other labels used were FITC-anti-P-selectin mAb (1:10) to detect P-selectin expression and PE-JON/A mAb (1:10) to detect integrin $\alpha_{IIb}\beta_3$ activation. For apoptosis induction, platelets were stimulated with the BH3 mimetic ABT-737 (1 μ M) for 1 h at 37°C (18). Washed mouse erythrocytes (1×10^{11} /L) were activated with ionomycin in the presence of 1 mM CaCl₂ at 37°C. Samples were analyzed with a BD FACS Calibur or BD Accuri C6 flow cytometer (Becton Dickinson, San Diego, CA, USA). Glycoprotein expression levels on platelets were determined by flow cytometry as described elsewhere (33). Data analysis was performed using the programs WinMDI (Becton Dickinson) or CFlow Plus (Becton Dickinson).

Light transmission measurements

Changes in light transmission were monitored in suspensions of washed platelets (1×10^{11} /L), activated with agonists in the presence of CaCl₂ (2 mM) under constant stirring at 37°C, using a Chronolog (Havertown, PA, USA) optical aggregometer.

Tirofiban (5 μ g/ml) was present if indicated. Hypotonic shock response (34) was induced by adding 125 μ l of distilled water with or without CaCl₂ (4 mM) and/or ionomycin (10 μ M) to 250 μ l PRP. Transmission changes were recorded with the Chronolog aggregometer under stirring at 37°C.

Whole-blood thrombus formation

Collagen-induced thrombus formation was assayed using PPACK/fragmin-anticoagulated human (35) or mouse (36) blood, basically as described. In brief, blood samples were flowed over a coverslip coated with collagen type-I in a transparent parallel-plate perfusion chamber, at a shear rate of 1000 s^{-1} for 4 min. Thrombi formed on the collagen surface were poststained with AF647-annexin A5, FITC-anti-CD62P mAb, and PE-JON/A mAb in (modified) HEPES buffer pH 7.45 supplemented with CaCl₂ (2 mM) and heparin (1 U/ml). Phase-contrast and fluorescence images were captured for analysis of surface area coverage of adherent platelets and of platelets with active integrins, P-selectin exposure or PS exposure (30). Image analysis was performed using Metamorph software version 7.5.0.0 (MDS Analytical Technologies, Sunnyvale, CA, USA) (37).

Western blot analyses

Washed platelet or erythrocyte suspensions were lysed with ice-cold 4 $\times$ lysis buffer (600 mM NaCl, 10 mM Tris, 4 mM EGTA, 4 mM EDTA, 4% NP40). Samples (5×10^7 human platelets, 1×10^8 mouse platelets) were separated on 8% SDS-PAGE gels, transferred to blotting membranes by semidry transfer (18). Membranes were immunostained with antibodies against K_{Ca}3.1, Ano1, Ano6 (all 1:1000), or integrin β_3 (Ab762, 1:10000; Ab754, 1:1000), and later reprobed with α -tubulin (1:1000). Incubation with secondary horseradish peroxidase-coupled antibody was overnight at 4°C, and visualization with an ECL system. Quantification was performed by densitometric analysis of stained blots, as described (18).

Statistics

Intervention effects were statistically compared with a paired sample Student's *t* test, using the statistical package for social sciences (SPSS, version 11.0; IBM SPSS, Chicago, IL, USA). Groups were compared by 2-way ANOVA (Bonferroni correction, if required).

RESULTS

Residual PS exposure and abolished swelling of Scott platelets during thrombus formation

Platelet aggregation and PS exposure (procoagulant activity) in response to the main collagen receptor, GPVI, can simultaneously be quantified in thrombi formed during whole-blood perfusion over a collagen surface (35, 38). In flow studies with blood from a patient with Scott syndrome (19), we established that platelet adhesion, aggregate formation, and α -granule secretion (expression of P-selectin) were similar to the platelet responses of healthy control subjects (Fig. 1A, B). In contrast, collagen-induced PS exposure was greatly reduced, but not completely abolished with the patient blood. Interestingly, the residual PS exposure appeared as patches on platelets with a normal,

Figure 1. Normal thrombus formation with residual PS exposure and abolished ballooning in Scott syndrome. Blood from healthy control subjects or patients with Scott syndrome was perfused over a collagen surface for 4 min at 1000 s^{-1} . Formed thrombi were stained with FITC- α CD62P (P-selectin) mAb and AF647-annexin A5 (PS exposure). **A)** Representative phase-contrast and fluorescence images (scale bars, $25\text{ }\mu\text{m}$), zoomed in as indicated (insets, $25 \times 25\text{ }\mu\text{m}$). Arrow (Scott) indicates nonballooning platelet with small patches of PS exposure. **B)** Surface area coverage (%SAC) of aggregated platelets, P-selectin expression, PS exposure, and ballooning. For PS exposure, dotted line indicates background fluorescence (no platelet thrombi). **C)** Western blots of control and Scott platelet lysates, stained for Ano6, and reprobbed with anti- α -tubulin mAb as lane loading control. Means $\pm$ SE ($n = 3$). * $P < 0.05$ (2-way ANOVA).

nonswollen shape (Fig. 1A, insets). This contrasted with the large, ballooning morphology (diameter, $\sim 10\text{ }\mu\text{m}$) of platelets from control subjects with high PS exposure. Quantification of the recorded microscopic images indicated that essentially no ballooning platelets were formed with Scott blood (Fig. 1A, right panel). Hence, the major defect of GPVI-dependent PS exposure in Scott platelets is accompanied by absence of platelet ballooning.

Identification of human *ANO6* splice variants

An explanation for the low PS exposure in patient's platelets may be residual expression of the *ANO6* gene. However, no Ano6 protein could be detected on Western blots from Scott platelets (Fig. 1C). This was confirmed by quantitative proteomic analysis (39), showing a >160 -fold reduction of identified Ano6 peptides in the Scott platelets (unpublished results). On the other hand, in line with a previous report (13), Ano6 mRNA was readily detectable in the patient's blood cells. RT-PCR analysis indicated expression of the default transcript as well as 2 alternatively spliced transcripts 1 and 2 (Supplemental Fig. 1). Due to the nature of the 2 mutations in the patient's cells (a splicing mutation in intron 6 and a frameshift mutation in exon 11), it is unlikely that these alternative transcripts are translated into a functional Ano6 protein, except for

some residual correctly spliced precursor mRNA transcribed from the IVS6 + 1G $\rightarrow$ A allele.

Reduced aggregation-independent light-transmission changes and integrin inactivation of Scott platelets

In platelets from control subjects, stimulation with convulxin/thrombin (stimulating GPVI and thrombin receptors) or ionomycin (Ca^{2+} ionophore, conditions as in Fig. 2A) resulted in 51 ± 3 and $85 \pm 11\%$ of PS-exposing platelets, respectively (means $\pm$ SE, $n = 8$). These values were not influenced by the integrin $\alpha_{\text{IIb}}\beta_3$ inhibitor, tirofiban ($P > 0.30$). In Scott platelets, the same agonists evoked severely reduced but residual PS exposure of 1.7 ± 0.5 and $2.0 \pm 0.6\%$ platelets ($n = 3$). Light transmission recording with control platelets indicated that convulxin/thrombin and ionomycin provoked rapid clearance of the cell suspensions; this effect was only partly reduced by tirofiban, inhibiting platelet aggregation (Fig. 2A, left panels). In line with earlier data (18), it is suggested that the residual increase in light transmission is due to shape change from discoid platelets to translucent, ballooned structures. Such ballooned platelets could indeed be observed by microscopy (Supplemental Fig. 2). In contrast, Scott platelets showed only limited changes in light transmission after stimulation in the presence of tirofiban (Fig. 2A, right panels).

Figure 2. Integrin $\alpha_{IIb}\beta_3$ -independent turbidity changes and reduced integrin cleavage by Scott syndrome platelets. **A)** Suspensions of washed platelets from control subjects or patients with Scott syndrome in CaCl_2 -containing medium were stimulated with convulxin (Cvx, 100 ng/ml) plus thrombin (Thr, 4 nM) or with ionomycin (Iono, 10 μM) in the presence or absence of tirofiban (2 $\mu\text{g}/\text{ml}$). Shown are representative changes in light transmission ($n = 3$). **B)** Hypotonic shock response of PRP induced by dilution (33%) in the presence or absence of CaCl_2 (4 mM). Shown are representative traces of changes in light transmission. **C)** Western blots probed for the intact and cleaved β_3 chain (detected with Ab762 and Ab754, respectively) of platelets stimulated with Cvx/Thr or Iono in the presence of CaCl_2 . Blots (representative for 3 performed) were reprobed with anti- α -tubulin mAb as lane loading control. **D)** Quantification of β_3 chain cleavage (5 min) from densitometric profiles. Means $\pm$ SE ($n = 4$ controls).

In this case, no ballooned structures were seen (Supplemental Fig. 2).

Light transmission changes due to platelet swelling can also be assessed in the hypotonic shock response, which measures the reaction of platelets in plasma to dilution with water (34). Water-induced light transmission changes were comparable for control and Scott platelets, even in the presence of CaCl_2 to stimulate Ca^{2+} -dependent ion fluxes (Fig. 2B). With CaCl_2 present, the late increase in light transmission accompanying balloon formation, however, was markedly delayed with Scott platelets. To determine a role of ion influxes, platelets were stimulated with ionomycin in hypertonic medium. Hypertonia resulted in delayed PS exposure and residual ballooning in control platelets, but failed to induce PS exposure or ballooning in Scott platelets (Supplemental Fig. 2).

In control cells, Ca^{2+} -induced PS exposure is accompanied by calpain-mediated cleavage of the integrin β_3 -chain, which results in inactivation of $\alpha_{IIb}\beta_3$ (18). Similarly, in Scott platelets stimulation with ionomycin resulted in rapid β_3 -chain cleavage, which was complete within 5 min (Fig. 2C, D). However, stimulation with convulxin/thrombin led

to a markedly delayed cleavage in the patient's platelets in comparison with control platelets. Together, these data point to a major defect in Ca^{2+} - and tonic-dependent light transmission clearance (balloon formation) and a partial defect in integrin β_3 -chain cleavage in Ca^{2+} -activated Scott platelets.

Subtle role of murine Gardos channels in platelet PS exposure and thrombus formation

Pharmacological studies with human platelets suggest a role for Gardos ($\text{K}_{\text{Ca}3.1}$) K^+ channels in agonist-induced PS exposure (22). We reinvestigated a role of these channels in $\text{Kcnn4}^{-/-}$ mice lacking the $\text{K}_{\text{Ca}3.1}$ protein. Western blot analysis indicated weak expression of the 47-kDa channel protein in platelets (platelets from Fig. 3A) and erythrocytes (not shown) of wild-type, but not of $\text{Kcnn4}^{-/-}$ mice. After stimulation with convulxin/thrombin or ionomycin, $\text{Kcnn4}^{+/+}$ and $\text{Kcnn4}^{-/-}$ platelets were equally high in PS exposure (Fig. 3B). Whole-blood perfusion over collagen resulted in subtle changes in thrombus formation (Fig. 3C).

Figure 3. Unchanged thrombus formation and PS exposure of mice lacking $K_{Ca}3.1$ Gardos channels. **A)** Expression of $K_{Ca}3.1$ protein in platelets from corresponding $Kcnn4^{+/+}$ and $Kcnn4^{-/-}$ mice; control lane refers to murine fibroblasts. Western blots are from cell lysates probed with anti-murine $K_{Ca}3.1$ mAb, and reprobed with anti- β -actin mAb as loading control. **B)** Washed platelets from $Kcnn4^{+/+}$ or $Kcnn4^{-/-}$ mice in $CaCl_2$ -containing medium were stimulated with convulxin (Cvx, 100 ng/ml) plus thrombin (Thr, 4 nM), or with ionomycin (Iono, 10 μ M), as indicated. Flow cytometric measurement of platelets binding A647-annexin A5, determined after 15 min. **C and D)** Blood from $Kcnn4^{+/+}$ and $Kcnn4^{-/-}$ mice was perfused over collagen for 4 min at 1000 s^{-1} . Thrombi were stained with PE-JON/A mAb (integrin activation) FITC- α CD62P mAb (P-selectin expression) and AF647-annexin A5 (PS exposure). **C)** Representative phase-contrast and fluorescence images (scale bars, 25 μ m). **D)** Quantitative analysis of surface area coverage (%SAC) of thrombi or fluorescence. Dotted line indicates background fluorescence for PS exposure (no platelet thrombi). Means $\pm$ SE ($n = 5-7$). * $P < 0.05$ (2-way ANOVA).

Whereas the overall deposition of $Kcnn4$ -deficient platelets was unchanged ($P > 0.1$), these platelets were slightly but significantly more increased in $\alpha_{IIb}\beta_3$ activation and PS exposure (Fig. 3D). Jointly, these data point to a minor negative rather than a positive role for the murine $K_{Ca}3.1$ channel in collagen-dependent PS exposure.

No role for murine *Ano1* in platelet PS exposure or thrombus formation

The isoform *Ano1* is a ubiquitously expressed ion channel displaying Ca^{2+} -dependent Cl^- conductance and has been implicated in hemolysis-induced PS exposure of erythrocytes (24, 40). Evaluation of platelets from mice with genetic deficiency in *Ano1* showed normal expression of the main surface glycoproteins (Supplemental Table 1) and normal activation in comparison to wild-type platelets with respect to agonist-induced integrin $\alpha_{IIb}\beta_3$ activation, P-selectin expression, and PS exposure (Supplemental Table 2). Measurements of whole-blood thrombus formation on collagen demonstrated that platelet deposition, P-selectin expression, and PS exposure were similar for *Ano1*-deficient and corresponding wild-type mice (Supplemental Fig. 3, $P > 0.1$).

Lethality of *Ano6*-deficient mice and identification of *Ano6* splice variants

Several approaches were followed to obtain mice with genetic deficiency of *Ano6*. In 2 laboratories, we generated heterozygous $Ano6^{+/+}$ mice using the stem cell clone AW-382, carrying a β -geo reporter gene trap in the *Ano6* gene

(*Ano6*^{AW} strain). These mice produced alive offspring with the gene trap insertion (data not shown), although at a lower number than expected. We hence investigated the embryos in heterozygous females at embryonic d 10.5, 12.5, and 16.5 of gestation. Morphologic examination indicated that at all time points, most embryos developed normally. However, several embryos were detected as death bodies, with exencephaly, or with signs of abdominal or intracranial bleeding (Fig. 4A, B). Western blot analysis indicated that platelets from surviving $Ano6^{AW/+}$ mice with gene trap insertion had significant expression of *Ano6* protein (Fig. 4C), and hence were not homozygously deficient in this gene.

In addition, we used heterozygous *Ano6*-deficient mice from the $Ano6^{Avor}$ strain, described before (29). Inbreeding resulted in offspring with ~30% of the expected number of $Ano6^{Avor/-}$ sucklings. In contrast to the $Ano6^{AW}$ strain, no lethality or obvious bleeding was seen in fetuses at embryonic d 14.5–18.5. As described previously (29), several deficient fetuses died around birth (e.g., due to asphyxia). However, ~30% of $Ano6^{-/-}$ mice survived longer than 2 mo ($Ano6^{Avor}$ strain), and these were used for phenotypic analysis. RT-PCR analyses of tissues from the surviving $Ano6^{Avor/-}$ mice (C57BL/6 background) showed residual *Ano6* mRNA expression, which was explained by the presence of alternative transcript 1 (Supplemental Fig. 4). Western blot analysis indicated that in platelets from $Ano6^{Avor/-}$ mice the 106 kDa *Ano6* protein was absent (Fig. 4D), thus indicating that the alternative transcript was not efficiently transcribed. Markedly, tail bleed time was prolonged in adult $Ano6^{Avor/-}$ mice (28.6 ± 7.5 min) in comparison with $Ano6^{Avor/+}$ (4.9 ± 1.8 min) and $Ano6^{Avo/+}$ (6.4 ± 1.6 min) animals (means $\pm$ SE, $n = 5-7$, $P < 0.05$).

A *Ano6^{AW}*

B *Ano6^{AW}*

C *Ano6^{AW}*

D *Ano6^{Avor}*

Figure 4. Embryonic lethality after breeding of *Ano6*-deficient mice. **A)** Viability of embryos generated by inbreeding of heterozygous *Ano6^{+/−}* mice (*Ano6^{AW}* strain) at gestational d (E) 10.5, 12.5, or 16.5. **B)** Embryo presenting with exencephaly (left, embryonic d 16.5), embryos presenting with major abdominal and intracranial bleeding (embryonic d 12.5). **C** and **D)** Westerns blots of *Ano6* protein expression in platelet lysates from heterozygous *Ano6^{+/−}* mice (*Ano6^{AW}* strain) (**C**) and homozygous *Ano6^{−/−}* mice (*Ano6^{Avor}* strain) (**D**).

Residual PS exposure and abolished swelling of *Ano6*-deficient mouse platelets in thrombus formation

We then compared activation characteristics of platelets from mice of the *Ano6^{AW}* and *Ano6^{Avor}* strains. Platelets from both types of heterozygous mice expressed normal levels of surface glycoproteins (Supplemental Table 1) and were unchanged in $\alpha_{IIb}\beta_3$ activation, P-selectin expression and PS exposure, when compared with corresponding wild-type platelets (Supplemental Table 2). Flow perfusion experiments, performed with *Ano6^{AW+/−}* or *Ano6^{Avor+/−}* blood did not reveal significant changes in parameters of thrombus formation, including PS exposure, in comparison with the wild-type blood (Supplemental Figs. 5 and 6). On the other hand, isolated erythrocytes from heterozygous *Ano6^{AW+/−}* or *Ano6^{Avor+/−}* mice displayed a significant lower ionomycin-induced PS exposure by 34.0 ± 6.6 or $31.6 \pm 8.1\%$, respectively, compared with corresponding wild-type erythrocytes (means $\pm$ SE, $n = 4-5$, $P < 0.05$).

We then assessed thrombus formation on collagen using blood from surviving adult homozygous deficient *Ano6^{−/−}* mice (*Ano6^{Avor}* strain). Thrombus formation as such was unchanged, with similar platelet adhesion, integrin $\alpha_{IIb}\beta_3$ activation and P-selectin expression, in comparison with thrombi from wild-type mice (Fig. 5A, B). However, although wild-type thrombi showed 1–2% of the surface as PS exposure, as before (18), the *Ano6^{Avor−/−}* thrombi displayed a substantial $76.2 \pm 2.6\%$ ($n = 4$, $P < 0.05$) reduction of this parameter (Fig. 5B). High-magnification images indicated residual patches of PS exposure in some of the collagen-bound *Ano6^{Avor−/−}* platelets (Fig. 5A, insert). Notably, these platelets with residual PS exposure were smaller than the 8 μ m ballooning structures seen with

wild-type platelets. Image quantification further learned that platelet ballooning was essentially abolished in *Ano6^{Avor−/−}* blood samples (Fig. 5B).

Activation studies indicated that ADP-, thrombin-, and convulxin-induced integrin activation and P-selectin expression were unaffected in washed *Ano6^{Avor−/−}* platelets (Supplemental Table 2). On the other hand, in these knockout platelets PS exposure in response to ionomycin (data not shown) or convulxin/thrombin (Fig. 6A, B) was strongly impaired. In $\sim 10\%$ of the platelets residual, low PS exposure was observed after stimulation with convulxin/thrombin.

Human Scott platelets display a partly reduced PS exposure in response to the apoptosis-stimulating agent ABT-737 (11). In particular, flow cytometric analysis of ABT-737-treated patient's platelets indicated a reduced fraction with high PS exposure (M3 fraction), and an increased fraction with moderate PS exposure (M2 fraction), which can form at minimal or low Ca^{2+} rises. We studied this ABT-737-induced response in *Ano6^{Avor−/−}* platelets and noted that, similarly, the M2 fraction (moderate PS exposure) was increased at the expense of the M3 fraction (high PS exposure), when compared with wild-type control platelets (Fig. 6C, D).

Impaired aggregation-independent light transmission changes and integrin inactivation of *Ano6*-deficient mouse platelets

Similarly to human platelets, wild-type mouse platelets stimulated with convulxin/thrombin or ionomycin showed light transmission changes in the presence of

Figure 5. Normal thrombus formation, residual PS exposure, and abolished ballooning in the absence of *Ano6*. Blood from corresponding *Ano6*^{+/+} and *Ano6*^{-/-} mice (*Ano6*^{Avor} strain) was perfused over collagen for 4 min at 1000 s⁻¹. Thrombi on the surface were stained as indicated for Fig. 3. A) Representative phase-contrast and fluorescence images (scale bars, 25 μ m; insets, 25 $\times$ 25 μ m). B) Surface area coverage (%SAC) of thrombi or fluorescence from integrin activation, P-selectin expression, PS exposure, and ballooning. Dotted line indicates background fluorescence for PS exposure (no platelet thrombi). Means $\pm$ SE ($n = 3$). * $P < 0.05$ (2-way ANOVA).

tirofiban to block platelet aggregation due to clearance of the platelet suspension (Fig. 7A). This clearance was substantially lower ($\sim 80\%$) for *Ano6*-deficient platelets. In PRP, we monitored the dilution-induced hypotonic shock response, which was similar for *Ano6*-deficient and wild-type platelets (Fig. 7B). Yet, with CaCl₂ present, the later increase in light transmission accompanying balloon formation was greatly delayed in the deficient platelets. Finally, we determined the cleavage of the integrin β_3 -chain in response to convulxin/thrombin, which remained partial for 30 min in *Ano6*^{Avor} platelets (reduction to $\sim 60\%$), whereas it was complete in this time frame in *Ano6*^{Avor} platelets (Fig. 7C, D). Ionomycin-induced β_3 -chain cleavage was not different in the presence or absence of *Ano6*. In control experiments, we established that the β_3 -chain cleavage was annulled by the calpain inhibitor

calpeptin, as described before (18), indicating it was due to calpain-dependent proteolytic activity. Together, these findings demonstrate a major deficiency in Ca²⁺-dependent light transmission clearance (balloon formation) and a partial defect in integrin β_3 -chain cleavage in platelets from the *Ano6*-deficient mice.

DISCUSSION

In the present work, we compared the activation properties of human Scott platelets with those of mouse platelets lacking one of the transmembrane proteins previously linked to PS exposure, the K_{Ca}3.1 Gardos channels or the *Ano1* or *Ano6*. Although pharmacological evidence (using clotrimazol and charybdotoxin) has suggested a positive

Figure 6. Residual Ca²⁺-dependent PS exposure by *Ano6*-deficient platelets. A and B) Washed platelets from corresponding *Ano6*^{+/+} and *Ano6*^{-/-} mice (*Ano6*^{Avor} strain) were stimulated in CaCl₂-containing medium with convulxin (Cvx 100 ng/ml) plus thrombin (Thr, 4 nM) for 30 min. C and D) Washed platelets were stimulated with the BH3 mimetic ABT-737 (10 μ M) for 1 h. Shown are representative histograms of AF647-annexin A5 binding after stimulation (black lines) or vehicle controls (gray lines). Markers M1, M2, and M3 indicate fractions of platelets with no, moderate, or high annexin A5 binding, respectively. Means $\pm$ SE ($n = 3-4$). * $P < 0.05$ vs. wild-type (2-way ANOVA).

Figure 7. Integrin $\alpha_{IIb}\beta_3$ -independent turbidity changes and reduced integrin cleavage by Ano6-deficient platelets. A) Suspensions of washed platelets from corresponding *Ano6*^{+/+} and *Ano6*^{-/-} mice (*Ano6*^{Avor} strain) in CaCl_2 -containing medium were stimulated with convulxin (Cvx, 100 ng/ml) plus thrombin (Thr, 4 nM) or with ionomycin (Iono, 10 μM) in the presence or absence of tirofiban (2 $\mu\text{g}/\text{ml}$). Shown are representative changes in light transmission ($n = 3$). B) Hypotonic shock response of PRP by water dilution (33%) in the presence or absence of CaCl_2 (4 mM). Shown are representative traces of changes in light transmission. C) Western blots probed for the intact and cleaved integrin β_3 chain (detected with Ab762 and Ab754, respectively) of platelets stimulated with Cvx/Thr or Iono (concentrations as above) in the presence of CaCl_2 . Blots (representative for 3 performed) were reprobed with anti- α -tubulin mAb as lane loading control. D) Quantification of β_3 chain cleavage from densitometric profiles. Means $\pm$ SE ($n = 3$). * $P < 0.05$.

role of the $\text{K}_{\text{Ca}}3.1$ channels in PS exposure in human platelets (22), we could not confirm this in *Kcnn4*^{-/-} mice. Instead, upon thrombus formation on collagen, $\text{K}_{\text{Ca}}3.1$ deficiency increased PS exposure along with integrin activation, suggesting that this channel suppresses rather than stimulates platelet activation. Assuming that the $\text{K}_{\text{Ca}}3.1$ channels act similarly in human and mouse platelets, the difference with previously published data (21, 22) might be explained by off-target effects of the pharmacological inhibitors used.

Ano1 can function as a Ca^{2+} -activated Cl^- channel (16, 23) and has been implicated in PS exposure in erythrocytes treated with α -hemolysin (24). In smooth muscle cells, Ano1 can regulate cell proliferation (40). In the present experiments, we could not confirm a role of Ano1 in Ca^{2+} -dependent PS exposure, given that *Ano1*^{-/-} mouse platelets responded normally to collagen, convulxin/thrombin, or ionomycin.

Earlier studies indicated that murine deficiency in Ano6 affects mineral deposition in skeletal tissue (29) and arterial thrombus formation *in vivo* (17). By cross-breeding we could obtain viable and adult *Ano6*^{-/-} offspring from mice of the *Ano6*^{Avor} but not of the *Ano6*^{AW} strain. Although this remains to be confirmed, the survival of the *Ano6*^{Avor-/-} mice might be related to the expression of alternative *Ano6* mRNA transcripts in key tissues. On the other hand, heterozygous *Ano6*^{AW+/+} and *Ano6*^{Avor+/+} mice

survived normally without obvious phenotypic defects. In the heterozygous mice, thrombus formation and platelet activation properties were unchanged in our hands, but heterozygous erythrocytes from both lines showed a reduced ionomycin-induced PS exposure.

Using blood from the surviving *Ano6*^{Avor-/-} mice, we found that collagen-dependent thrombus formation was unchanged in terms of platelet deposition, aggregation, integrin activation, and secretion. On the other hand, collagen-dependent PS exposure in platelets was greatly but not completely reduced, and morphologic changes to a ballooning structure were abolished. A similar, combined defect in platelet PS exposure and ballooning was observed with blood from the patients with Scott syndrome.

Phenotypic resemblance of the *Ano6*^{Avor-/-} and patient platelets was also noticed from flow cytometric studies. In both *Ano6*^{-/-} and Scott platelets, PS exposure was mostly, yet incompletely, reduced after convulxin/thrombin treatment and was slightly diminished upon apoptosis stimulation with ABT-737. Furthermore, the platelets from Ano6-deficient mice and the patients with Scott syndrome displayed a reduction in convulxin/thrombin-induced integrin β_3 cleavage, likely due to reduced calpain activation (18). Together, these data indicate that the functional and morphologic alterations found in platelets from the patients with Scott syndrome are quite well phenocopied in platelets from Ano6-deficient mice.

As summarized elsewhere (17, 23, 41, 42), Ano6 can function not only as a Ca^{2+} -dependent phospholipid scramblase but also as a chloride and cation channel. The inability of Ano6-deficient platelets to form balloons—like Scott platelets—suggests a defect in Ca^{2+} -dependent ion influx and swelling. This idea is confirmed by our finding that a hypertonic environment markedly delays the PS exposure and balloon formation. The swelling seems to be a consequence of multiple ion influxes, as we found that specific depletion of Cl^- or Na^+ ions was without effect (unpublished results). On the other hand, it should be noted that also other Ca^{2+} channels, in particular Orail and TRPC isoforms, can contribute to PS exposure in platelets (43, 44).

Scott syndrome has been described as a moderate bleeding disorder, with hemorrhagic episodes only after trauma or childbirth (2, 3). Although the syndrome is rare (with 3 patients characterized so far), it is likely underdiagnosed. The present data with *Ano6^{Avor-/-}* mice, despite a reduced survival, point to limited hemostatic insufficiency, as mouse tail bleed times were increased. The residual platelet PS exposure and delayed thrombin and fibrin generation in addition may explain the limited severity of bleeding. Interestingly, we have identified in both mouse and human samples alternative splice variants of Ano6. In agreement with this finding, also other authors describe the expression of Ano6 splice variants, which differ in their N-terminal cytoplasmic domains, but are similar in PS scrambling activities, in different human tissues (45). In humans, the nature of the 2 *ANO6* gene mutations in the patients with Scott syndrome leads to impaired translation of all identified splice variants. In mice, the tissue distribution of the splice variants is still unclear. These variants might be of functional importance during embryonic development and at later life. On the other hand, we could not detect Ano6 protein expression and hence found no evidence for a role of these splice variants, in the residual PS exposure in human Scott syndrome or mouse *Ano6^{Avor-/-}* platelets. Not unlikely, other Ca^{2+} -dependent Ano isoforms (23), enforced by Orail and TRPC Ca^{2+} entry channels (43, 44), may account for the low PS exposure in the absence of Ano6 channels. **[F]**

This work was supported by grants from the Cardiovascular Center Maastricht, and the Dutch Heart Foundation 2011T6 (to N.J.A.M., J.M.E.M.C., and J.W.M.H.), and Deutsche Forschungsgemeinschaft DFG SFB699, project A7&A12 (to R.S. and K.K.). The authors declare no conflicts of interest.

REFERENCES

- Sims, P. J., Wiedmer, T., Esmon, C. T., Weiss, H. J., and Shattil, S. J. (1989) Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. *J. Biol. Chem.* **264**, 17049–17057
- Toti, F., Satta, N., Fressinaud, E., Meyer, D., and Freyssinet, J. M. (1996) Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. *Blood* **87**, 1409–1415
- Satta, N., Toti, F., Fressinaud, E., Meyer, D., and Freyssinet, J. M. (1997) Scott syndrome: an inherited defect of the procoagulant activity of platelets. *Platelets* **8**, 117–124
- Munnix, I. C., Harmsma, M., Giddings, J. C., Collins, P. W., Feijge, M. A., Comfurius, P., Heemskerk, J. W., and Bevers, E. M. (2003) Store-mediated calcium entry in the regulation of phosphatidylserine exposure in blood cells from Scott patients. *Thromb. Haemost.* **89**, 687–695
- Bevers, E. M., Comfurius, P., and Zwaal, R. F. (1983) Changes in membrane phospholipid distribution during platelet activation. *Biochim. Biophys. Acta* **736**, 57–66
- Zwaal, R. F. A., and Schroit, A. J. (1997) Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. *Blood* **89**, 1121–1132
- Williamson, P., Christie, A., Kohlin, T., Schlegel, R. A., Comfurius, P., Harmsma, M., Zwaal, R. F. A., and Bevers, E. M. (2001) Phospholipid scramblase activation pathways in lymphocytes. *Biochemistry* **40**, 8065–8072
- Heemskerk, J. W., Mattheij, N. J., and Cosemans, J. M. (2013) Platelet-based coagulation: different populations, different functions. *J. Thromb. Haemost.* **11**, 2–16
- Schoenwaelder, S. M., Yuan, Y., Josefsson, E. C., White, M. J., Yao, Y., Mason, K. D., O'Reilly, L. A., Henley, K. J., Ono, A., Hsiao, S., Willcox, A., Roberts, A. W., Huang, D. C., Salem, H. H., Kile, B. T., and Jackson, S. P. (2009) Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. *Blood* **114**, 663–666
- Kmit, A., van Kruchten, R., Ousingsawat, J., Mattheij, N. J., Senden-Gijsbers, B., Heemskerk, J. W., Schreiber, R., Bevers, E. M., and Kunzelmann, K. (2013) Calcium-activated and apoptotic phospholipid scrambling induced by Ano6 can occur independently of Ano6 ion currents. *Cell Death Dis.* **4**, e611
- Van Kruchten, R., Mattheij, N. J., Saunders, C., Feijge, M. A., Swieringa, F., Wolfs, J. L., Collins, P. W., Heemskerk, J. W., and Bevers, E. M. (2013) Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation. *Blood* **121**, 1850–1857
- Suzuki, J., Umeda, M., Sims, P. J., and Nagata, S. (2010) Calcium-dependent phospholipid scrambling by TMEM16F. *Nature* **468**, 834–838
- Castoldi, E., Collins, P. W., Williamson, P. L., and Bevers, E. M. (2011) Compound heterozygosity for 2 novel TMEM16F mutations in a patient with Scott syndrome. *Blood* **117**, 4399–4400
- Brunner, J. D., Lim, N. K., Schenck, S., Duerst, A., and Dutzler, R. (2014) X-ray structure of a calcium-activated TMEM16 lipid scramblase. *Nature* **516**, 207–212
- Martins, J. R., Faria, D., Kongsuphol, P., Reisch, B., Schreiber, R., and Kunzelmann, K. (2011) Anoctamin 6 is an essential component of the outwardly rectifying chloride channel. *Proc. Natl. Acad. Sci. USA* **108**, 18168–18172
- Tian, Y., Schreiber, R., and Kunzelmann, K. (2012) Anoctamins are a family of Ca^{2+} -activated Cl^- channels. *J. Cell Sci.* **125**, 4991–4998
- Yang, H., Kim, A., David, T., Palmer, D., Jin, T., Tien, J., Huang, F., Cheng, T., Coughlin, S. R., Jan, Y. N., and Jan, L. Y. (2012) TMEM16F forms a Ca^{2+} -activated cation channel required for lipid scrambling in platelets during blood coagulation. *Cell* **151**, 111–122
- Mattheij, N. J., Gilio, K., van Kruchten, R., Jobe, S. M., Wieschhaus, A. J., Chishti, A. H., Collins, P., Heemskerk, J. W., and Cosemans, J. M. (2013) Dual mechanism of integrin $\alpha_{\text{IIb}}\beta_3$ closure in procoagulant platelets. *J. Biol. Chem.* **288**, 13325–13336
- Clark, S. R., Thomas, C. P., Hammond, V. J., Aldrovandi, M., Wilkinson, G. W., Hart, K. W., Murphy, R. C., Collins, P. W., and O'Donnell, V. B. (2013) Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation. *Proc. Natl. Acad. Sci. USA* **110**, 5875–5880
- Okada, Y., Shimizu, T., Maeno, E., Tanabe, S., Wang, X., and Takahashi, N. (2006) Volume-sensitive chloride channels involved in apoptotic volume decrease and cell death. *J. Membr. Biol.* **209**, 21–29
- Lang, P. A., Kaiser, S., Myssina, S., Wieder, T., Lang, F., and Huber, S. M. (2003) Role of Ca^{2+} -activated K^+ channels in human erythrocyte apoptosis. *Am. J. Physiol. Cell Physiol.* **285**, C1553–C1560
- Wolfs, J. L., Wielders, S. J., Comfurius, P., Lindhout, T., Giddings, J. C., Zwaal, R. F., and Bevers, E. M. (2006) Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. *Blood* **108**, 2223–2228
- Suzuki, J., Fujii, T., Imao, T., Ishihara, K., Kuba, H., and Nagata, S. (2013) Calcium-dependent phospholipid scramblase activity of TMEM16 protein family members. *J. Biol. Chem.* **288**, 13305–13316

24. Skals, M., Jensen, U. B., Ousingsawat, J., Kunzelmann, K., Leipziger, J., and Praetorius, H. A. (2010) Escherichia coli α -hemolysin triggers shrinkage of erythrocytes via $K_{Ca}3.1$ and TMEM16A channels with subsequent phosphatidylserine exposure. *J. Biol. Chem.* **285**, 15557–15565
25. Siljander, P., Farndale, R. W., Feijge, M. A., Comfurius, P., Kos, S., Bevers, E. M., and Heemskerk, J. W. (2001) Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: Involvement of p38 MAP kinase and calpain. *Arterioscler. Thromb. Vasc. Biol.* **21**, 618–627
26. Grgic, I., Kaistha, B. P., Paschen, S., Kaistha, A., Busch, C., Si, H., Köhler, K., Elsässer, H. P., Hoyer, J., and Köhler, R. (2009) Disruption of the Gardos channel ($K_{Ca}3.1$) in mice causes subtle erythrocyte macrocytosis and progressive splenomegaly. *Pflugers Arch.* **458**, 291–302
27. Si, H., Heyken, W. T., Wölfle, S. E., Tysiac, M., Schubert, R., Grgic, I., Vilianovich, L., Giebing, C., Maier, T., Gross, V., Bader, M., de Wit, C., Hoyer, J., and Köhler, R. (2006) Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca^{2+} -activated K^{+} channel. *Circ. Res.* **99**, 537–544
28. Brähler, S., Kaistha, A., Schmidt, V. J., Wölfle, S. E., Busch, C., Kaistha, B. P., Kacik, M., Hasenau, A. L., Grgic, I., Si, H., Bond, C. T., Adelman, J. P., Wulff, H., de Wit, C., Hoyer, J., and Köhler, R. (2009) Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. *Circulation* **119**, 2323–2332
29. Ehlen, H. W., Chinenkova, M., Moser, M., Munter, H. M., Krause, Y., Gross, S., Brachvogel, B., Wuelling, M., Kornak, U., and Vortkamp, A. (2013) Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues. *J. Bone Miner. Res.* **28**, 246–259
30. Van Kruchten, R., Cosemans, J. M., and Heemskerk, J. W. (2012) Measurement of whole blood thrombus formation using parallel-plate flow chambers - a practical guide. *Platelets* **23**, 229–242
31. Van der Meijden, P. E., Feijge, M. A., Swieringa, F., Gilio, K., Nergiz-Unal, R., Hamulyák, K., and Heemskerk, J. W. (2012) Key role of integrin $\alpha_{IIb}\beta_3$ signaling to Syk kinase in tissue factor-induced thrombin generation. *Cell. Mol. Life Sci.* **69**, 3481–3492
32. Kuijpers, M. J., van der Meijden, P. E., Feijge, M. A., Mattheij, N. J., May, F., Govers-Riemslog, J., Meijers, J. C., Heemskerk, J. W., Renné, T., and Cosemans, J. M. (2014) Factor XII regulates the pathological process of thrombus formation on ruptured plaques. *Arterioscler. Thromb. Vasc. Biol.* **34**, 1674–1680
33. Deppermann, C., Cherpokova, D., Nurden, P., Schulz, J. N., Thielmann, I., Kraft, P., Vögtle, T., Kleinschnitz, C., Dütting, S., Krohne, G., Eming, S. A., Nurden, A. T., Eckes, B., Stoll, G., Stegner, D., and Nieswandt, B. (2013) Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice. *J. Clin. Invest.* **123**, 3331–3342
34. Holme, S., Moroff, G., and Murphy, S.; Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. (1998) A multi-laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. *Transfusion* **38**, 31–40
35. De Witt, S. M., Swieringa, F., Cavill, R., Lamers, M. M., van Kruchten, R., Mastenbroek, T., Baaten, C., Coort, S., Pugh, N., Schulz, A., Scharrer, I., Jurk, K., Zieger, B., Clemetson, K. J., Farndale, R. W., Heemskerk, J. W., and Cosemans, J. M. (2014) Identification of platelet function defects by multi-parameter assessment of thrombus formation. *Nat. Commun.* **5**, 4257
36. Gilio, K., Munnix, I. C., Mangin, P., Cosemans, J. M., Feijge, M. A., van der Meijden, P. E., Olieslagers, S., Chrzanowska-Wodnicka, M. B., Lillian, R., Schoenwaelder, S., Koyasu, S., Sage, S. O., Jackson, S. P., and Heemskerk, J. W. (2009) Non-redundant roles of phosphoinositide 3-kinase isoforms α and β in glycoprotein VI-induced platelet signaling and thrombus formation. *J. Biol. Chem.* **284**, 33750–33762
37. De Witt, S., Swieringa, F., Cosemans, J. M., and Heemskerk, J. W. (2014) Thrombus formation on microspotted arrays of thrombogenic surfaces. *Nat. Protocol Exchange* **2014**, 3309
38. Kuijpers, M. J., Schulte, V., Bergmeier, W., Lindhout, T., Brakebusch, C., Offermanns, S., Fässler, R., Heemskerk, J. W., and Nieswandt, B. (2003) Complementary roles of glycoprotein VI and $\alpha_2\beta_1$ integrin in collagen-induced thrombus formation in flowing whole blood ex vivo. *FASEB J.* **17**, 685–687
39. Burkhart, J. M., Vaudel, M., Gambaryan, S., Radau, S., Walter, U., Martens, L., Geiger, J., Sickmann, A., and Zahedi, R. P. (2012) The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. *Blood* **120**, e73–e82
40. Wang, M., Yang, H., Zheng, L. Y., Zhang, Z., Tang, Y. B., Wang, G. L., Du, Y. H., Lv, X. F., Liu, J., Zhou, J. G., and Guan, Y. Y. (2012) Downregulation of TMEM16A calcium-activated chloride channel contributes to cerebrovascular remodeling during hypertension by promoting basilar smooth muscle cell proliferation. *Circulation* **125**, 697–707
41. Kunzelmann, K., Nilius, B., Owsianik, G., Schreiber, R., Ousingsawat, J., Sirianant, L., Wanitchakool, P., Bevers, E. M., and Heemskerk, J. W. (2014) Molecular functions of anoctamin 6 (TMEM16F): a chloride channel, cation channel, or phospholipid scramblase? *Pflugers Arch.* **466**, 407–414
42. Shimizu, T., Iehara, T., Sato, K., Fujii, T., Sakai, H., and Okada, Y. (2013) TMEM16F is a component of a Ca^{2+} -activated Cl^{-} channel but not a volume-sensitive outwardly rectifying Cl^{-} channel. *Am. J. Physiol. Cell Physiol.* **304**, C748–C759
43. Harper, M. T., Londoño, J. E., Quick, K., Londoño, J. C., Flockerzi, V., Philipp, S. E., Birnbaumer, L., Freichel, M., and Poole, A. W. (2013) Transient receptor potential channels function as a coincidence signal detector mediating phosphatidylserine exposure. *Sci. Signal.* **6**, ra50
44. Van Kruchten, R., Braun, A., Feijge, M. A., Kuijpers, M. J., Rivera-Galdos, R., Kraft, P., Stoll, G., Kleinschnitz, C., Bevers, E. M., Nieswandt, B., and Heemskerk, J. W. (2012) Anti-thrombotic potential of blockers of store-operated calcium channels in platelets. *Arterioscler. Thromb. Vasc. Biol.* **32**, 1717–1723
45. Scudieri, P., Caci, E., Venturini, A., Sondo, E., Pianigiani, G., Marchetti, C., Ravazzolo, R., Pagani, F., and Galletta, L. J. (2015) Ion channel and lipid scramblase activity associated with expression of TMEM16F/ANO6 isoforms. *J. Physiol.* **593**, 3829–3848

Received for publication August 30, 2015.

Accepted for publication October 5, 2015.